The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial report of treatment of uveal melanoma with hepatic metastases with yttrium90 internal radiation followed by ipilimumab and nivolumab.
 
David R. Minor
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Nektar
Consulting or Advisory Role - theravance
 
Takami Sato
Consulting or Advisory Role - Castle Biosciences; Immunocore
 
Marlana M. Orloff
Consulting or Advisory Role - Immunocore
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Immunocore (Inst); Plexxikon (Inst)
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Actym Therapeutics; Aduro Biotech; Akrevia Therapeutics; Alphamab; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Benevir; Bristol-Myers Squibb; Compugen; Eisai; EMD Serono; IDEAYA Biosciences; Immunocore; Incyte; Janssen; Jounce Therapeutics; Leap Therapeutics; Mavu Pharmaceutical; Merck; Mersana; Novartis; Partner Therapeutics; Reflexion Medical; Spring Bank; Synlogic; Tempest Therapeutics; TTC Oncology; Vividion Therapeutics
Research Funding - Abbvie (Inst); Array BioPharma; Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Checkmate Pharmaceuticals; Compugen (Inst); Corvus Pharmaceuticals (Inst); Delcath Systems (Inst); Evelo Therapeutics; Five Prime Therapeutics (Inst); FLX Bio; Genentech/Roche (Inst); Immunocore (Inst); Incyte (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Palleon Pharmaceuticals; Pharmacyclics (Inst); Tesaro (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Akrevia Therapeutics; Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Castle Biosciences; Checkmate Pharmaceuticals; EMD Serono; Gilead Sciences; IDEAYA Biosciences; Immunocore; Janssen; Jounce Therapeutics; Merck; Mersana; Novartis; Reflexion Medical
 
David J. Eschelman
No Relationships to Disclose
 
Carin F. Gonsalves
No Relationships to Disclose
 
Robert D. Adamo
No Relationships to Disclose
 
Ricky T Tong
No Relationships to Disclose
 
Devron H. Char
No Relationships to Disclose
 
Rani Anne
No Relationships to Disclose
 
Kevin B. Kim
Stock and Other Ownership Interests - Cryoport; Cryoport (I)
Honoraria - Array BioPharma; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Novartis; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Novartis; Seattle Genetics/Astellas
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
Research Funding - Amgen; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis; Seattle Genetics/Astellas